Ronald N. Marcus, MD
Ronald N. Marcus, MD, has served as Vice President of Research and Development since April 2018. Dr Marcus has more than 25 years in developing neuroscience pharmaceutical products. Dr. Marcus served as Chief Medical Officer (CMO) and Head of Regulatory from 2015 to 2018, at Cerecor where he led the clinical, operations, regulatory and research teams that developed drugs across a wide range of neurological and psychiatric disorders, including treatment resistant depression, epilepsy and Parkinson's Disorder. From 2014-2015, Dr Marcus served as CMO at Spinifex. From 1991 to 2013, Dr. Marcus served as Executive Director, Neuroscience Global Clinical Research at Bristol-Myers Squibb (BMS). In this role he was Early Development Team Leader for neuropathic pain, schizophrenia and migraine compounds and Life-Cycle Management (LCM) Team Leader for Abilify. In addition to the approval of over 20 NDAs and sNDAs globally for Abilify, Dr Marcus also led the successful development of Serzone, an antidepressant at BMS. Dr Marcus received a BA in Psychology from University of Virginia. He earned his medical degree from SUNY Buffalo and completed his Psychiatry residency and NIMH Research Fellowship at Cornell University, New York Hospital-Westchester Division. He has authored more than 80 peer-reviewed publications.